Image Courtesy: Twitter

HIGHLIGHTS:

  • The Serum Institute currently has a partnership with the UK’s Oxford University-AstraZeneca trial and the US’ Novavax trial
  • The Bill& Melinda foundation will provide a risk funding of $150 million for the same
  • Novavax Inc claimed it has entered a supply and license confirmation with the SII for the development and commercialization of its COVID-19 vaccine candidate
  • The Drugs Controller General of India (DCGI) has endorsed SII to conduct Phase II and III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India

NEW DELHI: The world’s largest vaccine manufacturer Serum Institute of India (SII) has partnered with Gavi and the Bill and Melinda Gates Foundation to make 100 million doses of Covid-19 vaccine for $3 each. The vaccine will affordable to low and middle-income countries in 2021. The Serum Institute currently has a partnership with the UK’s Oxford University-AstraZeneca trial and the US’ Novavax trial. The Bill & Melinda foundation will provide a risk funding of $150 million for the same. The SII will get the funding from the Gates Foundation through international vaccine alliance GAVI.

SII claimed that the vaccines will be available for purchasing if they are successful in accomplishing full licensure and pass World Health Organization screening. Novavax Inc claimed it has entered a supply and license confirmation with the SII for the development and commercialization of its COVID-19 vaccine candidate. Reportedly, SII will attain the exclusive rights for the vaccine in India during the period of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those appointed by the World Bank as upper-middle or high-income countries.

Previously Novavax claimed that its experimental COVID-19 vaccine contains high levels of antibodies that can fight the novel virus in early-stage clinical trials. The company is going to start its III phase trials in late September. Chief executive officer of SII, Adar Poonawalla stated the partnership with Novavax will enhance the power of the vaccine technologies. The Drugs Controller General of India (DCGI) has endorsed SII to conduct Phase II and III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.

Oxford’s COVID-19 vaccine has shown a definitive outcome in its initial trial with the vaccine producing a dual immune response in people aged 18 to 55. Dr Poonawalla, on Oxford’s COVID-19 vaccine production, stated we have two dedicated facilities to produce millions of doses of the COVID-19 vaccine while withholding the vast production of other products amidst the pandemic situation. Presumedly around 2-3 million doses of the Oxford COVID-19 vaccine is manufactured by the company for getting the process accurate.

LEAVE A REPLY

Please enter your comment!
Please enter your name here